11th Mar 2016 12:57
LONDON (Alliance News) - Onzima Ventures PLC said Friday that its investee company N4 Pharma Ltd has expanded its intellectual property portfolio, buying rights for a wide range of patents from Scotland-based Opal IP Ltd, as well as entering into a consultancy services agreement with Opal.
N4 has bought a range of patents covering new uses and formulations of many leading off patent or soon to come off patent drugs.
Under the consultancy services agreement Opal will provide patent and formulation support for N4's Cocrys technology.
Onzima has a 49% stake in N4 Pharma.
"This arrangement with Opal massively extends our capability for formulating new versions of drugs with huge commercial potential. It also brings us access to world leading experts to develop new patents and opportunities for the cocrystal products we are already developing using Cocrys," said N4 Pharma Chief Executive Officer Nigel Theobald in a statement.
Shares in Onzima Ventures were trading up 25% at 1.08 pence Friday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
ONZ.L